Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population-Reference-Cited by-同舟云学术

Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population

Published:2023-02-17 Issue:3 Volume:77 Page:931-941
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:

Author:

Udompap Prowpanga,Therneau Terry M.,Canning Rachel E.,Benson Joanne T.,Allen Alina M.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.32739

Reference22 articles.

1. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease;Gastroenterology,2021

2. Modelling the cost effectiveness of non‐alcoholic fatty liver disease risk stratification strategies in the community setting;PLoS One,2021

3. Low accuracy of FIB‐4 and NAFLD fibrosis scores for screening for liver fibrosis in the population;Clin Gastroenterol Hepatol,2021

4. Is there an association between commonly employed biomarkers of liver fibrosis and liver stiffness in the general population?;Ann Hepatol,2020

5. Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes;Diabetes Care,2020

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying and Linking Patients At Risk for MASLD with Advanced Fibrosis to Care in Primary Care;Journal of General Internal Medicine;2024-07-26

2. Performance of novel collagen turnover biomarkers to detect increased liver stiffness in MASLD;Journal of Internal Medicine;2024-07-03

3. Metabolic Dysfunction–Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction;Gastroenterology;2024-07

4. Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population;Alimentary Pharmacology & Therapeutics;2024-03-18

5. The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease;Liver International;2024-03-15